SEARCH:   Advanced

Blood, 1 March 2004, Vol. 103, No. 5, pp. 1791-1795. Prepublished online as a Blood First Edition Paper on November 6, 2003; DOI 10.1182/blood-2003-09-3023. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-09-3023v1 103/5/1791    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Stebbing, J. Articles by Savage, P. Search for Related Content PubMed PubMed Citation Articles by Stebbing, J. Articles by Savage, P. Related Collections Immunobiology Neoplasia Immunotherapy Brief Reports Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY Brief report Antibody-targeted MHC complex–directed expansion of HIV-1– and KSHV-specific CD8+ lymphocytes: a new approach to therapeutic vaccination Justin Stebbing, Brian Gazzard, Steve Patterson, Mark Bower, Dhayaneethie Perumal, Mark Nelson, Andrew McMichael, Graham Ogg, Agamemnon Epenetos, Frances Gotch, and Philip Savage From the Department of Immunology, Division of Investigative Science, Faculty of Medicine, Imperial College of Science, Technology, and Medicine, The Chelsea and Westminster Hospital, London, United Kingdom. The ability of therapeutic vaccines to generate large numbers of CD8+ T lymphocytes that have specificity for HIV-1 or other virally infected cells has enormous potential clinical value. However, approaches to produce cytotoxic T lymphocytes (CTLs) in vivo via vaccine technology have thus far been disappointing and the ex vivo production of cells for adoptive transfer is labor intensive and expensive. We describe the results of a 2-step antibody-targeting system for the production of CD8+ T lymphocytes specific for HIV-1 and Kaposi sarcoma–associated herpesvirus (KSHV), suitable for use in vivo. In 8 consecutive human leukocyte antigen–A2 (HLA-A2)–positive HIV-1–infected individuals with Kaposi sarcoma, 2 cycles of this system resulted in more than 1 Log increases of specific anti-HIV and anti-KSHV CD8+ lymphocytes. These expanded cells have an effector phenotype that includes the ability to produce interferon- and CD45Ra+/CD69+ staining. We have shown that antibody-targeted B cells can function as effective antigen-presenting molecules and lead to sustained specific T-lymphocyte expansion from peripheral blood mononuclear cells (PBMCs) of immunosuppressed individuals. This approach, which offers an easy and effective protocol for the amplification of specific antiviral and antitumor CTLs, may offer significant advances for in vivo T-cell immunotherapeutic protocols. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. Stebbing, A. Sanitt, A. Teague, T. Powles, M. Nelson, B. Gazzard, and M. Bower Prognostic Significance of Immune Subset Measurement in Individuals With AIDS-Associated Kaposi's Sarcoma J. Clin. Oncol., June 1, 2007; 25(16): 2230 - 2235. [Abstract] [Full Text] [PDF] V. Cesson, K. Stirnemann, B. Robert, I. Luescher, T. Filleron, G. Corradin, J.-P. Mach, and A. Donda Active Antiviral T-Lymphocyte Response Can Be Redirected against Tumor Cells by Antitumor Antibody x MHC/Viral Peptide Conjugates Clin. Cancer Res., December 15, 2006; 12(24): 7422 - 7430. [Abstract] [Full Text] [PDF] M. Bower, N. McCall-Peat, N. Ryan, L. Davies, A. M. Young, S. Gupta, M. Nelson, B. Gazzard, and J. Stebbing Protease inhibitors potentiate chemotherapy-induced neutropenia Blood, November 1, 2004; 104(9): 2943 - 2946. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020